Merck Heart, Kidney Drug Fails Late-Stage Clinical Trial
By wchung | 24 Mar, 2026
Merck and Co. said Friday its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo.
The company said rolofylline did not reach its primary or secondary goals in the late-stage trial. Based on the results, Merck said it no longer plans to ask the Food and Drug Administration to approve the drug candidate this year.
The trial also showed that 30 mg of rolofylline did not reduce the risk of death or hospitalization due to heart or kidney problems 60 days after treatment, and that it did not reduce kidney impairment.
Merck is still analyzing study data from the study, which is called PROTECT, and it will present full results from the 2,033-patient trial at a medical conference later this year.
In morning trading, Merck shares fell 64 cents, or 2.4 percent, to $25.94.
6/5/2009 10:04 AM WHITEHOUSE STATION, N.J. (AP)
Articles
- World's 25 Most Polluted Cities All in India, Pakistan and China
- Flight Cancellation Spread Across Globe on Mideast Hub Closures
- S. Korea Calls for Nationwide Campaign to Conserve Fuel
- Vietnam Airlines Cancels Flights Due to Jet Fuel Shortage
- Alibaba's 5-nm Agentic AI Chip Unveiled As World's Most Powerful RISC-VCPU
- What's Ro Khanna's Angle with Thomas Massie?
- Top 5 Date Turn-Offs for Women and Men
- Demand Builds for Affordable Chinese EVs Among American Carbuyers
- OpenAI Bumps Up Minimum Return to 17.5% in Competition with Anthropic for Private Equity
- China's Open-Source AI Dominates Global Downloads, Threatens US Leadership